Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Boehringer Ingelheim
Boehringer Ingelheim
ArriVent BioPharma, Inc.
Seagen Inc.
Eli Lilly and Company
Pfizer
Tomsk National Research Medical Center of the Russian Academy of Sciences
University Hospital Heidelberg
M.D. Anderson Cancer Center
Daiichi Sankyo
City of Hope Medical Center
RemeGen Co., Ltd.
University of Chicago
Amgen
Replimune Inc.
Debiopharm International SA
Arcus Biosciences, Inc.
Erasca, Inc.
Arcus Biosciences, Inc.
Bayer
M.D. Anderson Cancer Center
Pfizer
Boehringer Ingelheim
Boehringer Ingelheim
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Genentech, Inc.
AstraZeneca
H. Lee Moffitt Cancer Center and Research Institute
Poseida Therapeutics, Inc.
Werewolf Therapeutics, Inc.
Roswell Park Cancer Institute
Novartis
Astellas Pharma Inc
AstraZeneca
Corregene Biotechnology Co., Ltd
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
Eli Lilly and Company
Boundless Bio, Inc.
Seagen Inc.
Novartis
Novartis
Pfizer
Seagen Inc.